cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
There exist dozens of recognized schools or orientations of psychotherapy—the list below represents a few influential orientations not given above. Although they all have some typical set of techniques practitioners employ, they are generally better known for providing a framework of theory and philosophy that guides a therapist in his or her working with a client.
John Bennett Fenn (June 15, 1917 – December 10, 2010) was an American analytical chemist who was awarded a share of the Nobel Prize in Chemistry in 2002, sharing half of the award with Koichi Tanaka for their work in mass spectrometry (the other half went to Kurt Wüthrich). His contributions related to the development of electrospray ionization, now a commonly used technique for large molecules and routine liquid chromatography-tandem mass spectrometry. Early in his career, he studied the field of jet propulsion at Project SQUID and focused on molecular beams. He finished his career with more than 100 publications, including one book. Fenn was born in New York City, and moved to Kentucky with his family during the Great Depression. Fenn did his undergraduate work at Berea College, and received his PhD from Yale. He worked in industry at Monsanto and at private research labs before moving to academic posts including Yale and Virginia Commonwealth University. Fenn's research into electrospray ionization found him at the center of a legal dispute with Yale University. He lost the lawsuit, after it was determined that he misled the university about the potential usefulness of the technology. Yale was awarded $500,000 in legal fees and $545,000 in damages. The decision pleased the university, but provoked mixed responses from some people affiliated with the institution, who were disappointed with the treatment of a Nobel Prize winner with such a long history at the school.
=== Global food distribution === Along with Archer Daniels Midland, Bunge, and Cargill, the Louis Dreyfus Company is one of the four "ABCD" companies that dominate world agricultural commodity trading.
== Return to Mexico == On September 25, 1945, a few weeks after the war ended, members of the FAEM unveiled a monument to their fallen comrades. The monument was designed by pilot Miguel Moreno Arreola and was built with the help of 10 elements of the Squadron. The eagle that tops the monument was made by the sculptor of Filipino origin Guillermo Tolentino. On October 12, the Squadron handed over its aircraft to the 45th Air Services Group and began preparations to return to Mexico. The members of the FAEM boarded the Sea Marlin ship on October 23, arriving on November 13 in San Pedro, California, although the first to arrive in Americas were Colonel Cárdenas Rodríguez, Lieutenant Amadeo Castro Almanza, Second Lieutenant García Ramos and Second Lieutenant José Luis Pratt Ramos, who traveled by air after meeting with General MacArthur in Tokyo, to thank him for his cooperation with the FAEM. 201st Squadron returned to Mexico City on November 18 in a military parade in the Zócalo and the subsequent presentation of the flag to the president, General Manuel Ávila Camacho, being received as heroes for battling fascism in the Pacific. The FAEM was disbanded upon his return from the Philippines. However, the rest of the Mexicans who fought in other armies were not given recognition as they did with the Squadron. In the years following the war, many of the members have successfully moved on to other careers in life, some as leaders of civil aviation or the Mexican Army, others as businessmen, educators and engineers; five of the pilots became generals of the Mexican Air Force.
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
Sources: en.wikipedia.org
== Early life and education == Tanaka was born and raised in Toyama, Japan, his biological mother died one month after he was born. Tanaka graduated from Tohoku University with a bachelor's degree in electrical engineering in 1983, afterward he joined Shimadzu Corporation, where he engaged in the development of mass spectrometers.
==== Poland ==== There is a large pool of think tanks in Poland on a wide variety of subjects. The oldest state-sponsored think tank is The Western Institute in Poznań (Polish: Instytut Zachodni). The second oldest is the Polish Institute of International Affairs (PISM) established in 1947. Another notable state-sponsored think tank is the Centre for Eastern Studies (OSW), which specializes in the countries neighboring Poland and in the Baltic Sea region, the Balkans, Turkey, the Caucasus and Central Asia. Among the private think tanks notable organizations include the Institute for Structural Research (IBS) on economic policy, The Casimir Pulaski Foundation on foreign policy, the Institute of Public Affairs (ISP) on social policy, and the Sobieski Institute.
On July 28, 2019, during the XXV São Paulo Forum hosted in Caracas, Nicolás Maduro declared that the FARC-EP dissident leaders Iván Márquez and Jesús Santrich were "welcome" in Venezuela and to the São Paulo Forum.
Misoprostol has a variety of uses in obstetrics and gynecology. It is also used to relieve pain from duodenal ulcers when other treatments have been ineffective. Misoprostol can be used to induce labor in patients at the end of pregnancy. It causes cervical ripening, or the thinning and shortening of the cervix in preparation for birth. It also causes uterine contractions, allowing the body to expel the baby. For this purpose, it is placed inside the vagina. Misoprostol is also used to prevent and treat postpartum hemorrhage (PPH), or uncontrolled bleeding following childbirth. The World Health Organization estimates that PPH causes 70,000 maternal deaths each year. Misoprostol induces uterine contractions, encouraging the uterus to shrink after childbirth. This shrinking puts pressure on blood vessels on the uterus, forcing them to close rather than continue to bleed. To prevent PPH, misoprostol is given orally or dissolved under the tongue immediately after delivery. To treat PPH, it is given orally, dissolved under the tongue, or placed in the rectum. For the management of miscarriage in the first trimester of pregnancy, misoprostol is used to completely empty the uterus. This is important because the patient may develop an infection if they retain the products of conception. Misoprostol causes uterine contractions, forcing the body to expel the pregnancy. It can be used alone, but it is more effective in conjunction with mifepristone. Misoprostol is swallowed, placed inside the vagina, or dissolved in the mouth for this purpose.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.